AI Article Synopsis
- Atherosclerosis involves chronic inflammation and fat buildup in arteries, leading to vascular issues.
- PCSK9 is a key enzyme that affects LDL cholesterol levels and is now understood to also contribute to atherosclerosis by influencing inflammation.
- The relationship between PCSK9 and the apoER2 receptor, which plays an anti-inflammatory role in atherosclerosis, suggests that targeting this interaction could be a novel approach to managing inflammation in vascular disease.
Article Abstract
Atherosclerosis is characterized by chronic inflammation and lipid accumulation in arterial walls, resulting in several vascular events. Proprotein convertase subtilisin kexin 9 (PCSK9), a serine protease, has a pivotal role in the degradation of hepatic low-density lipoprotein receptor (LDLR). It can increase plasma concentrations of low-density lipoprotein cholesterol and affect lipid metabolism. Recently, PCSK9 has been found to accelerate atherosclerosis via mechanisms apart from that involving the degradation of LDLR, with an emerging role in regulating the inflammatory response in atherosclerosis. Apolipoprotein E receptor 2 (apoER2), one of the LDLR family members expressed in macrophages, can bind to its ligand apolipoprotein E (apoE), exhibiting an anti-inflammatory role in atherosclerosis. Evidence suggests that apoER2 is a target of PCSK9. This review aims to discuss PCSK9 as a potential regulator of apoE/apoER2 against inflammation in atherosclerosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cca.2018.04.040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!